PROTALIX BIOTHERAPEUTICS INC's ticker is PLX and the CUSIP is 74365A309. A total of 31 filers reported holding PROTALIX BIOTHERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 1.33 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $248,336 | -72.7% | 149,600 | -67.2% | 0.00% | – |
| Q2 2023 | $911,128 | -17.2% | 455,564 | -13.0% | 0.00% | – |
| Q1 2023 | $1,100,190 | +91.1% | 523,900 | +24.6% | 0.00% | – |
| Q4 2022 | $575,811 | -0.0% | 420,300 | -24.2% | 0.00% | – |
| Q3 2022 | $576,000 | +16.8% | 554,561 | +22.7% | 0.00% | – |
| Q2 2022 | $493,000 | +40.9% | 452,100 | +36.7% | 0.00% | – |
| Q1 2022 | $350,000 | +9.4% | 330,619 | -13.9% | 0.00% | – |
| Q4 2021 | $320,000 | -65.2% | 383,900 | -44.5% | 0.00% | – |
| Q3 2021 | $919,000 | -57.2% | 691,271 | -38.5% | 0.00% | – |
| Q2 2021 | $2,148,000 | +7.7% | 1,124,545 | +151.5% | 0.00% | – |
| Q1 2021 | $1,994,000 | +74.9% | 447,113 | +42.5% | 0.00% | – |
| Q4 2020 | $1,140,000 | +461.6% | 313,778 | +497.7% | 0.00% | – |
| Q3 2020 | $203,000 | -67.7% | 52,500 | -68.4% | 0.00% | – |
| Q2 2020 | $629,000 | +914.5% | 165,900 | +533.2% | 0.00% | – |
| Q1 2020 | $62,000 | – | 26,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | 2,413,487 | $2,513,000 | 0.04% |
| CAPITAL PERFORMANCE ADVISORS LLP | 25,974 | $27,000 | 0.02% |
| MEITAV INVESTMENT HOUSE LTD | 244,332 | $256,000 | 0.01% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 133,790 | $139,000 | 0.00% |
| IHT Wealth Management, LLC | 22,000 | $23,000 | 0.00% |
| Psagot Value Holdings Ltd. / (Israel) | 6,000 | $6,000 | 0.00% |
| Smith Salley Wealth Management | 12,048 | $13,000 | 0.00% |
| BANK OF AMERICA CORP /DE/ | 3,027 | $3,000 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |
| DAVENPORT & Co LLC | 22,000 | $23,000 | 0.00% |